Stock DBVT DBV TECHNOLOGIES S.A.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings DBV Technologies S.A. Nasdaq

Equities

DBVT

US23306J1016

Market Closed - Nasdaq
Other stock markets
 04:30:00 2024-05-03 pm EDT 		5-day change 1st Jan Change
0.6669 USD -0.46% Intraday chart for DBV Technologies S.A. -2.21% -30.01%
Apr. 23 European Equities Traded in the US as American Depositary Receipts Jump in Tuesday Trading MT
Apr. 22 European Equities Traded in the US as American Depositary Receipts Rebound in Monday Trading MT

Summary

  • On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.

Strengths

  • Thanks to a sound financial situation, the firm has significant leeway for investment.
  • For the past twelve months, EPS forecast has been revised upwards.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.

Weaknesses

  • According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
  • The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
  • The company has insufficient levels of profitability.
  • The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
  • The overall consensus opinion of analysts has deteriorated sharply over the past four months.
  • Over the past twelve months, analysts' consensus has been significantly revised downwards.
  • The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.

Ratings chart - Surperformance

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
DBV TECHNOLOGIES S.A. Stock DBV Technologies S.A.
-30.01% 125M -
MERCK KGAA Stock Merck KGaA
+5.48% 69.91B
A
KYOWA KIRIN CO. LTD. Stock Kyowa Kirin Co. Ltd.
+12.55% 9.24B
A-
SK BIOPHARMACEUTICALS CO., LTD. Stock SK Biopharmaceuticals Co., Ltd.
-13.75% 5.05B
A-
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD. Stock Shenyang Xingqi Pharmaceutical Co.,Ltd.
+42.38% 4.47B -
YUHAN CORPORATION Stock Yuhan Corporation
+4.51% 3.92B
B-
BETTA PHARMACEUTICALS CO., LTD. Stock Betta Pharmaceuticals Co., Ltd.
-19.05% 2.41B
C-
CHANGCHUN BCHT BIOTECHNOLOGY CO. Stock Changchun BCHT Biotechnology Co.
-28.72% 2.23B -
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD. Stock Shanghai Shyndec Pharmaceutical Co., Ltd.
+11.13% 2.02B - -
SUPERNUS PHARMACEUTICALS, INC. Stock Supernus Pharmaceuticals, Inc.
+6.53% 1.66B
D+
Investor Rating
Trading Rating
-
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
-
EV / Sales
-
Price to Book
-
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. DBV Stock
  4. DBVT Stock
  5. Ratings DBV Technologies S.A.